---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-085044"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2024-07-22T23:59:59+00:00"
generated_at: "2026-05-31T18:37:15.231248+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvalent doses first patient in Phase 1 trial of HER2-selective inhibitor NVL-330 for NSCLC

## Summary
- Initiated HEROEX-1 Phase 1a/1b trial evaluating NVL-330 in pre-treated patients with HER2-altered NSCLC.
- First patient dosed on July 22, 2024; trial will assess safety, tolerability, PK, and preliminary anti-tumor activity.
- Trial objectives include determination of recommended Phase 2 dose (RP2D) for NVL-330.

## SEC filing metadata
- accession: 0000950170-24-085044
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2024-07-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017024085044/0000950170-24-085044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017024085044/nuvl-20240722.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-085044
- JSON: https://secwatch.observer/filing/0000950170-24-085044.json
- Plain text: https://secwatch.observer/filing/0000950170-24-085044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.